Subscribe To

Price Alert Latest News Economic Calendar News

DMTTF / Canaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year results

Canaccord Genuity (TSX:CF, LSE:CF) analysts have repeated a 'Speculative Buy' rating and $1.00 price target on Small Pharma Inc (TSX-V:DMT, OTCQB:DMTTF) after the biotechnology company published its financial results for the year ended February 28, 2022. They noted that Small Pharma showed a smaller-than-expected net loss of $4.8 million versus their loss estimate of $7 million. Read More

Demo Live Account See Partner Details

Content Topics

Canaccord

Genuity

Repeats

Speculative

Buy

Rating

00 speculative

Target

Pharma

Following

Publication

Full year

Results

Stock

DMTTF

Posted: Jun 13 2022, 11:45

Author Name: Proactive Investors

DMTTF News

By GlobeNewsWire
March 1, 2023

Small Pharma to Present at Cowen's 43rd Annual Health Care Conference

Company will also host a cocktail reception on Tuesday, March 7 Company will also host a cocktail reception on Tuesday, March 7

By GlobeNewsWire
January 24, 2023

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology comp

By GlobeNewsWire
September 8, 2022

Small Pharma to Participate in Upcoming September Investor Conferences

LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology com

By Proactive Investors
June 13, 2022

Canaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year results

Canaccord Genuity (TSX:CF, LSE:CF) analysts have repeated a 'Speculative Buy' rating and $1.00 price target on Small Pharma Inc (TSX-V:DMT, OTCQB:DMT

By GlobeNewsWire
May 30, 2022

Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022

LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology compa

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.